Your best medicine news resource
May 17th 2008Drug InformationCholesterol
Poor cholesterol management may not only affect a man’s risk for prostate cancer, but also his risk of biomedical recurrence after prostatectomy, according to new data from Duke University.
More: continued here
May 15th 2008Drug InformationCholesterol
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ‘Tredaptive’? (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
More: continued here
May 15th 2008Drug InformationCholesterol
At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.
More: continued here
May 15th 2008Drug InformationCholesterol
The results of a University of Illinois study have demonstrated an effective way to lower cholesterol levels - by eating chocolate bars.”Eating two CocoaVia dark chocolate bars a day not only lowered cholesterol, it had the unexpected effect of also lowering systolic blood pressure,” said John Erdman, a U. of I. professor of food science and human nutrition.The study, funded in part by Mars Inc.
More: continued here
May 15th 2008Drug InformationCholesterol
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).
More: continued here
May 15th 2008Drug InformationCholesterol
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE? (nicotinic acid/ laropiprant, MSD) 1000 mg/20 mg tablets for patients with dyslipidemia or primary hypercholesterolemia. Separately, the U.S.
More: continued here
May 15th 2008Drug InformationCholesterol
Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company’s New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia. “We plan to meet with the FDA and to submit additional information to enable the agency to further evaluate the benefit/risk profile of MK-0524A,” said Peter S. Kim, Ph. D.
More: continued here
May 15th 2008Drug InformationCholesterol
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company’s Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect. “The Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated.
More: continued here
May 15th 2008Drug InformationCholesterol
In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface. Interestingly, polarity was not significantly affected by this approach. The association of CEA to lipid rafts, cholesterol, and sphingolipid-enriched microdomains was inhibited in parallel.This study, performed by a team led by Dr.
More: continued here
May 15th 2008Drug InformationCholesterol
Randox produces high quality apolipoprotein tests for the diagnosis, monitoring and research of cardiovascular disease and related conditions. Apolipoproteins are essential components of lipoproteins, for example HDL and LDL, responsible for transporting cholesterol and triglycerides around the body. Six apolipoprotein tests are available from Randox: Apo A-I, Apo A-II, Apo B, Apo C-II, Apo C-III and Apo E.
More: continued here
Your best medicine news resource
